
Teladoc Health, Inc. (NYSE:TDOC – Free Report) – Equities research analysts at Zacks Research boosted their FY2026 earnings per share (EPS) estimates for shares of Teladoc Health in a research report issued on Wednesday, November 18th. Zacks Research analyst Team now forecasts that the health services provider will post earnings per share of ($0.87) for the year, up from their prior estimate of ($0.89). The consensus estimate for Teladoc Health’s current full-year earnings is ($0.85) per share. Zacks Research also issued estimates for Teladoc Health’s Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.17) EPS, Q4 2027 earnings at ($0.25) EPS, FY2027 earnings at ($0.91) EPS, Q1 2028 earnings at ($0.17) EPS, Q3 2028 earnings at ($0.12) EPS and FY2028 earnings at ($0.64) EPS.
Teladoc Health (NYSE:TDOC – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.63%. The company had revenue of $605.10 million during the quarter, compared to analysts’ expectations of $588.14 million. During the same period last year, the business earned ($0.28) EPS. The business’s quarterly revenue was down 3.4% on a year-over-year basis.
View Our Latest Analysis on Teladoc Health
Teladoc Health Price Performance
Teladoc Health stock opened at $7.46 on Friday. The firm has a 50-day moving average of $6.95 and a 200-day moving average of $6.67. Teladoc Health has a one year low of $4.40 and a one year high of $9.89. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -8.68 and a beta of 2.00.
Hedge Funds Weigh In On Teladoc Health
Several institutional investors and hedge funds have recently made changes to their positions in TDOC. American Century Companies Inc. lifted its holdings in shares of Teladoc Health by 94.3% during the 3rd quarter. American Century Companies Inc. now owns 9,511,923 shares of the health services provider’s stock worth $55,169,000 after acquiring an additional 4,617,419 shares during the period. Algert Global LLC increased its stake in Teladoc Health by 42.6% in the third quarter. Algert Global LLC now owns 203,810 shares of the health services provider’s stock valued at $1,182,000 after acquiring an additional 60,910 shares during the last quarter. Virtu Financial LLC increased its stake in Teladoc Health by 40.4% in the third quarter. Virtu Financial LLC now owns 41,030 shares of the health services provider’s stock valued at $238,000 after acquiring an additional 11,814 shares during the last quarter. New York State Common Retirement Fund raised its position in Teladoc Health by 22.7% during the third quarter. New York State Common Retirement Fund now owns 63,203 shares of the health services provider’s stock valued at $367,000 after purchasing an additional 11,700 shares in the last quarter. Finally, Allworth Financial LP raised its position in Teladoc Health by 65.5% during the third quarter. Allworth Financial LP now owns 4,863 shares of the health services provider’s stock valued at $28,000 after purchasing an additional 1,925 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.
Insiders Place Their Bets
In other news, insider Carlos Nueno sold 29,432 shares of the firm’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $9.20, for a total transaction of $270,774.40. Following the completion of the sale, the insider owned 35,312 shares in the company, valued at approximately $324,870.40. This trade represents a 45.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Charles III sold 17,805 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the sale, the chief executive officer owned 465,535 shares of the company’s stock, valued at approximately $2,839,763.50. This represents a 3.68% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 47,892 shares of company stock valued at $383,086. Company insiders own 0.70% of the company’s stock.
More Teladoc Health News
These are some of the TDOC news items that stood out recently:
- Positive Sentiment: Truist Financial raised its price target to $9 from $8, while keeping a hold rating. The higher target is a favorable signal, though the unchanged rating indicates the firm is not recommending a buy. Teladoc Health coverage
- Positive Sentiment: Zacks Research improved its forecasts for FY2026 EPS to a loss of $0.87 from $0.89, and FY2027 EPS to a loss of $0.91 from $0.98. It also raised several quarterly estimates, including Q3 2027, where its projected loss narrowed to $0.17 from $0.26. Teladoc Health coverage
- Neutral Sentiment: The estimate revisions were mixed: Zacks lowered its Q4 2026, Q1 2028, and Q4 2027 forecasts, but raised or maintained several other estimates. It still expects Teladoc to report losses in the forecast periods, including a projected FY2028 loss of $0.64 per share. Teladoc Health coverage
About Teladoc Health
Teladoc Health, Inc. provides virtual healthcare services through a digital platform that connects individuals with clinicians and other health professionals. Its offerings include virtual primary and specialty care, mental health services, and support for managing chronic conditions. The company serves members in the United States and internationally, with services and availability varying by market. Its consumer mental health services include BetterHelp, while its chronic-care programs draw on technology and services developed by Livongo, which Teladoc acquired in 2020.
Featured Articles
- Five stocks we like better than Teladoc Health
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
